Share Twitter LinkedIn Facebook Email Dr. Jack West summarizes key data from the IMpower131 trial of patients with advanced squamous NSCLC & examines whether the carboplatin/nab-paclitaxel/atezolizumab combination is a strong treatment option in this patient setting.
Immunotherapy Side Effects Under Scrutiny: New Data on Bone Density and T-Cell Insights AACR 3 Mins Read
Immunotherapy Revolution Unveiled: How TLS-Derived Antibodies Are Changing Cancer Treatment AACR Io 2025 AACR 4 Mins Read
AACR IO 2025: Revolutionary Insights into Desmoplastic Melanoma Treatment – Kari L Kendra, MD, PHD AACR 5 Mins Read